According to the Wise Finance app, AstraZeneca (AZN.US) announced that the Phase III WAYPOINT study of Tezspire (tezepelumab) for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) has achieved the co-primary endpoints. The results showed that the tezepelumab treatment group demonstrated statistically and clinically significant reductions in nasal polyps and relief in nasal congestion symptoms.

Public information shows that Tezepelumab, a first-in-class monoclonal antibody jointly developed by AstraZeneca and Amgen, can inhibit thymic stromal lymphopoietin (TSLP). TSLP is a key epithelial cell cytokine located upstream in various inflammatory cascades and is associated with diseases such as asthma, CRSwNP, chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis (EoE). Tezspire can block TSLP, thereby preventing the release of pro-inflammatory cytokines by immune cells, effectively treating related diseases.

Tezepelumab is currently approved in the United States for the treatment of severe asthma and is undergoing Phase III clinical trials in China. In addition to CRSwNP, Tezepelumab is also being developed for other potential indications, including COPD and EoE.